Evaluating the Newly Proposed ARDS Definition in Hospitalized Patients With COVID-19 Treated With High-Flow Nasal Oxygen

被引:1
|
作者
Isha, Shahin [1 ]
Olaizola, Gustavo [2 ,3 ]
Bisso, Indalecio Carboni [2 ]
Raavi, Lekhya [1 ]
Jonna, Sadhana [1 ]
Jenkins, Anna [1 ]
Hanson, Abby [1 ]
Kashyap, Rahul [1 ,4 ]
Monzon, Veronica [5 ]
Huespe, Ivan A. [2 ,3 ]
Sanghavi, Devang [1 ]
机构
[1] Mayo Clin, Jacksonville, FL USA
[2] Hosp Italiano Buenos Aires, Buenos Aires, Argentina
[3] Univ Buenos Aires, Buenos Aires, Argentina
[4] Well Span Hlth, York, PA USA
[5] Hosp Italiano Agustin Roca, Buenos Aires, Argentina
关键词
ARDS; coronavirus disease 2019; high-flow nasal cannula oxygen; oxygen saturation; critical care; RESPIRATORY-DISTRESS-SYNDROME;
D O I
10.4187/respcare.11933
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Background: The new Global definition of ARDS recently introduced a subgroup known as non-intubated ARDS. This study aimed to assess the risk of progression from noninvasive oxygen support to intubation and ARDS severity based on the S<INF>pO<INF>2</INF></INF>/F<INF>IO<INF>2</INF></INF> among non-intubated subjects with ARDS. Methods: This retrospective study included subjects with COVID-19 admitted to 7 hospitals (5 in the United States and 2 in Argentina) from January 2020-January 2023. Subjects meeting the new non-intubated ARDS definition (high-flow nasal cannula [HFNC] with an S<INF>pO<INF>2</INF></INF>/F<INF>IO<INF>2</INF></INF> <= 315 [with S<INF>pO<INF>2</INF></INF> <= 97%] or a P<INF>aO<INF>2</INF></INF>/F<INF>IO<INF>2</INF></INF> <= 300 mm Hg while receiving >= 30 L/min O<INF>2</INF> via HFNC) were included. The study evaluated the proportion of subjects who progressed to intubation, severity levels using the S<INF>pO<INF>2</INF></INF>/F<INF>IO<INF>2</INF></INF> cutoff proposed in the new ARDS definition, and mortality. Results: Nine hundred sixty-five non-intubated subjects with ARDS were included, of whom 27% (n = 262) progressed to meet the Berlin criteria within a median of 3 d (interquartile range 2-6). The overall mortality was 23% (95% CI 20-26) (n = 225), and among subjects who progressed to the Berlin criteria, it was 37% (95% CI 31-43) (n = 98). Additionally, the worst S<INF>pO<INF>2</INF></INF>/F<INF>IO<INF>2</INF></INF> within 1 d of ARDS diagnosis was correlated with mortality, with mortality rates of 26% (95% CI 23-30) (n = 177) for subjects with S<INF>pO<INF>2</INF></INF>/F<INF>IO<INF>2</INF></INF> <= 148, 17% (95% CI 12-23) (n = 38) for those with S<INF>pO<INF>2</INF></INF>/F<INF>IO<INF>2</INF></INF> between 149-234, and 16% (95% CI 8-28) (n = 10) for subjects maintaining an S<INF>pO<INF>2</INF></INF>/F<INF>IO<INF>2</INF></INF> higher than 235 (P < .001). Conclusions: The non-intubated ARDS criteria encompassed a broader spectrum of subjects with lower in-hospital mortality compared to the Berlin criteria. The S<INF>pO<INF>2</INF></INF>/F<INF>IO<INF>2</INF></INF> and ARDS severity cutoff proposed in the new Global ARDS definition were valuable predictors of in-hospital mortality in these subjects.
引用
收藏
页码:119 / 125
页数:7
相关论文
共 50 条
  • [1] Interhospital transfer of COVID-19 patients treated with high-flow nasal oxygen therapy
    Dubie, Elophe
    Morin, Francois
    Savary, Dominique
    Serruys, Amaury
    Usseglio, Pascal
    INTERNATIONAL JOURNAL OF EMERGENCY MEDICINE, 2021, 14 (01)
  • [2] Interhospital transfer of COVID-19 patients treated with high-flow nasal oxygen therapy
    Elophe Dubie
    François Morin
    Dominique Savary
    Amaury Serruys
    Pascal Usseglio
    International Journal of Emergency Medicine, 2021, 14
  • [3] The use of high-flow nasal oxygen in COVID-19
    Lyons, C.
    Callaghan, M.
    ANAESTHESIA, 2020, 75 (07) : 843 - 847
  • [4] PREDICTORS OF SPONTANEOUS PNEUMOMEDIASTINUM IN PATIENTS WITH COVID-19 AND ARDS ON HIGH-FLOW NASAL CANNULA
    Espinosa, Cynthia
    Morente, Laura Mendez
    Mansour, Ephraim H.
    Yousefzadeh, Michelle L.
    Muzaffarr, Zuleikha M.
    Salguero, Douglas
    Vianna, Sofia Durscki
    Quesada, Luisa D.
    Poli, Sergio
    Garcia, Hernando
    CHEST, 2022, 162 (04) : 1360A - 1361A
  • [5] High-Flow Nasal Oxygen and Noninvasive Ventilation for COVID-19
    Al-Dorzi, Hasan M.
    Kress, John
    Arabi, Yaseen M.
    CRITICAL CARE CLINICS, 2022, 38 (03) : 601 - 621
  • [6] Broadening the Berlin definition of ARDS to patients receiving high-flow nasal oxygen: an observational study in patients with acute hypoxemic respiratory failure due to COVID-19
    Fleur-Stefanie L. I. M. van der Ven
    Christel M. A. Valk
    Siebe Blok
    Michelle G. Brouwer
    Dai Ming Go
    Amanda Lokhorst
    Pien Swart
    David M. P. van Meenen
    Frederique Paulus
    Marcus J. Schultz
    Annals of Intensive Care, 13
  • [7] Broadening the Berlin definition of ARDS to patients receiving high-flow nasal oxygen: an observational study in patients with acute hypoxemic respiratory failure due to COVID-19
    van der Ven, Fleur-Stefanie L. I. M.
    Valk, Christel M. A.
    Blok, Siebe
    Brouwer, Michelle
    Go, Dai Ming
    Lokhorst, Amanda
    Swart, Pien
    van Meenen, David M. P.
    Paulus, Frederique
    Schultz, Marcus
    PRoAcT COVID Study Investigators
    ANNALS OF INTENSIVE CARE, 2023, 13 (01)
  • [8] Evaluating the New ARDS Definition in a Retrospective Cohort Analysis of Hospitalized COVID-19 Patients
    Isha, S.
    Olaizola, G.
    Bisso, I. Carboni
    Raavi, L.
    Jonna, S.
    Jenkins, A.
    Hanson, A.
    Kashyap, R.
    Huespe, I.
    Sanghavi, D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
  • [9] High-flow nasal oxygen: a safe, efficient treatment for COVID-19 patients not in an ICU
    Guy, Tiphaine
    Creachcadec, Audrey
    Ricordel, Charles
    Sale, Alexandre
    Arnouat, Baptiste
    Bizec, Jean-Louis
    Langelot, Marie
    Lineau, Christine
    Marquette, David
    Martin, Francoise
    Lederlin, Mathieu
    Jouneau, Stephane
    EUROPEAN RESPIRATORY JOURNAL, 2020, 56 (05)
  • [10] High-flow nasal oxygen in severe COVID-19 pneumonia and tocilizumab
    Mandal, M.
    Mazza, M.
    Esquinas, A. M.
    INFECTIOUS DISEASES NOW, 2022, 52 (05): : 324 - 325